Behçet’s syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments

[1]  Hilal Eser-Ozturk,et al.  The Results of Interferon-Alpha Treatment in Behçet Uveitis , 2020, Ocular immunology and inflammation.

[2]  G. Hatemi,et al.  Behçet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils , 2019, Front. Immunol..

[3]  F. Gao,et al.  Effectiveness and safety of interferon α2a as an add-on treatment for refractory Behçet’s uveitis , 2019, Therapeutic advances in chronic disease.

[4]  N. Taddei,et al.  Behçet’s syndrome as a tool to dissect the mechanisms of thrombo‐inflammation: clinical and pathogenetic aspects , 2018, Clinical and experimental immunology.

[5]  M. Gilio,et al.  Distribution of rs17482078 and rs27044 ERAP1 polymorphisms in a group of Italian Behçet’s syndrome patients: a preliminary case–control study , 2019, Internal and Emergency Medicine.

[6]  A. Amedei,et al.  The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review , 2019, Rheumatology International.

[7]  E. Seyahi.  Phenotypes in Behçet’s syndrome , 2019, Internal and Emergency Medicine.

[8]  G. Virgili,et al.  Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study , 2019, Mediators of inflammation.

[9]  S. Serdaroğlu,et al.  Pathergy testing: prospective comparison of dermatoscopic evaluation and naked eye examination , 2019, Internal and Emergency Medicine.

[10]  H. Yazici,et al.  Assessment of deep venous thrombosis in the lower extremity in Behçet’s syndrome: MR venography versus Doppler ultrasonography , 2019, Internal and Emergency Medicine.

[11]  E. Silvestri,et al.  Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study. , 2019, Journal of autoimmunity.

[12]  G. Hatemi,et al.  Update on the treatment of Behçet’s syndrome , 2019, Internal and Emergency Medicine.

[13]  M. Galeazzi,et al.  Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis. , 2019, Clinical and experimental rheumatology.

[14]  M. Galeazzi,et al.  Efficacy of anti-tumor necrosis factor-alpha monoclonal antibodies in patients with noninfectious anterior uveitis , 2019 .

[15]  G. Mumcu,et al.  Triggering agents and microbiome as environmental factors on Behçet’s syndrome , 2018, Internal and Emergency Medicine.

[16]  T. Ergun,et al.  Does illness perception associate with disease symptoms in Behçet’s disease? , 2018, Internal and Emergency Medicine.

[17]  E. Silvestri,et al.  Vascular Behçet’s syndrome: an update , 2018, Internal and Emergency Medicine.

[18]  G. Emmi,et al.  Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet’s disease , 2018, Internal and Emergency Medicine.

[19]  T. Ergun,et al.  The assessment of contributing factors to oral ulcer presence in Behçet’s disease: Dietary and non-dietary factors , 2018, European journal of rheumatology.

[20]  M. Galeazzi,et al.  The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet’s Disease , 2018, Ocular immunology and inflammation.

[21]  M. Galeazzi,et al.  Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients , 2018, Clinical Rheumatology.

[22]  Chunyan Wu,et al.  A metagenomic study of the gut microbiome in Behcet’s disease , 2018, Microbiome.

[23]  A. Vaglio,et al.  Adalimumab‐Based Treatment Versus Disease‐Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome , 2018, Arthritis & rheumatology.

[24]  D. Kim,et al.  OP0082 Apremilast for behÇet’s syndrome: a phase iii randomised, placebo-controlled, double-blind study (RELIEF) , 2018, WEDNESDAY, 13 JUNE 2018:.

[25]  M. Galeazzi,et al.  Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies , 2018, Clinical Rheumatology.

[26]  A. Vaglio,et al.  Hemoptysis in Behçet’s syndrome: from bedside to bench? , 2018, Internal and Emergency Medicine.

[27]  M. Galeazzi,et al.  Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab , 2018, Clinical Rheumatology.

[28]  R. Moots,et al.  2018 update of the EULAR recommendations for the management of Behçet’s syndrome , 2018, Annals of the rheumatic diseases.

[29]  M. Galeazzi,et al.  Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis , 2018, Clinical Rheumatology.

[30]  M. Antoine,et al.  Transcatheter embolotherapy of pulmonary artery aneurysms as emergency treatment of hemoptysis in Behcet patients: experience of a referral center and a review of the literature , 2018, Internal and Emergency Medicine.

[31]  G. Hatemi,et al.  Behçet syndrome: a contemporary view , 2018, Nature Reviews Rheumatology.

[32]  P. Bowness,et al.  Is Behçet's disease a ‘class 1‐opathy’? The role of HLA‐B*51 in the pathogenesis of Behçet's disease , 2018, Clinical and experimental immunology.

[33]  S. Yurdakul,et al.  Exacerbation of Behçet's syndrome and familial Mediterranean fever with menstruation. , 2017, Clinical and experimental rheumatology.

[34]  M. Park,et al.  Behçet’s disease risk association fine-mapped on the IL23R–IL12RB2 intergenic region in Koreans , 2017, Arthritis Research & Therapy.

[35]  R. Dhôte,et al.  Dietary and Nondietary Triggers of Oral Ulcer Recurrences in Behçet's Disease , 2017, Arthritis care & research.

[36]  M. Galeazzi,et al.  Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study , 2017, British Journal of Ophthalmology.

[37]  M. Resche-Rigon,et al.  Ustekinumab for Behçet's disease. , 2017, Journal of autoimmunity.

[38]  M. Galeazzi,et al.  Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study , 2017, Internal and Emergency Medicine.

[39]  E. Silvestri,et al.  Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study , 2017, Clinical Rheumatology.

[40]  T. Ergun,et al.  Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease. , 2016, Clinical immunology.

[41]  E. Remmers,et al.  A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers , 2016, Annals of the rheumatic diseases.

[42]  J. Shimizu,et al.  Bifidobacteria Abundance-Featured Gut Microbiota Compositional Change in Patients with Behcet’s Disease , 2016, PloS one.

[43]  P. Westerweel,et al.  Oral ulcerations after placement of orthodontic braces and skin pustules after laser hair removal: novel inducers of pathergy reactions in new-onset Behçet's disease , 2016, BMJ Case Reports.

[44]  Rosanna Abbate,et al.  Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet Disease , 2016, Circulation.

[45]  H. Direskeneli,et al.  Dual effects of testosterone in Behcet's disease: implications for a role in disease pathogenesis , 2013, Genes and Immunity.

[46]  M. Galeazzi,et al.  Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study , 2016, Clinical Rheumatology.

[47]  I. Olivieri,et al.  Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study , 2016, Clinical Rheumatology.

[48]  E. Remmers,et al.  The immunogenetics of Behçet's disease: A comprehensive review. , 2015, Journal of autoimmunity.

[49]  I. Sousa,et al.  Brief Report: Association of CCR1, KLRC4, IL12A–AS1, STAT4, and ERAP1 With Behçet's Disease in Iranians , 2015, Arthritis & rheumatology.

[50]  A. Gül.  Pathogenesis of Behçet’s disease: autoinflammatory features and beyond , 2015, Seminars in Immunopathology.

[51]  S. Rampelli,et al.  Behçet's syndrome patients exhibit specific microbiome signature. , 2015, Autoimmunity reviews.

[52]  S. Oliveira,et al.  Characterization of the major histocompatibility complex locus association with Behçet’s disease in Iran , 2015, Arthritis Research & Therapy.

[53]  C. Salvarani,et al.  Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet. , 2015, Seminars in arthritis and rheumatism.

[54]  Javier Martín,et al.  Epistatic Interaction of ERAP1 and HLA-B in Behçet Disease: A Replication Study in the Spanish Population , 2014, PloS one.

[55]  P. D. de Bakker,et al.  Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity , 2014, Proceedings of the National Academy of Sciences.

[56]  E. Silvestri,et al.  Reply: anti-IL1 blocking agents in drug-resistant Behçet's syndrome: our little case series. , 2014, Clinical and experimental rheumatology.

[57]  M. D’Elios,et al.  Behçet’s syndrome pathophysiology and potential therapeutic targets , 2014, Internal and Emergency Medicine.

[58]  E. Silvestri,et al.  Anakinra for resistant Behçet uveitis: why not? , 2013, Clinical and experimental rheumatology.

[59]  Akira Meguro,et al.  Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1 , 2013, Nature Genetics.

[60]  H. Yazıcı,et al.  Behçet Syndrome: Is It One Condition? , 2012, Clinical Reviews in Allergy & Immunology.

[61]  G. Hatemi,et al.  Behçet's syndrome and micro-organisms. , 2011, Best practice & research. Clinical rheumatology.

[62]  Christopher I. Amos,et al.  Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R/IL12RB2 regions associated with Behçet's disease , 2010, Nature Genetics.

[63]  U. Karaçayli,et al.  The close association between dental and periodontal treatments and oral ulcer course in behcet's disease: a prospective clinical study. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[64]  G. Mumcu,et al.  The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease. , 2007, Clinical and experimental rheumatology.

[65]  H. Direskeneli,et al.  Activation of neutrophils by testosterone in Behçet's disease. , 2007, Clinical and experimental rheumatology.

[66]  R. Wolf,et al.  Recurrent aphthous stomatitis and smoking , 2000, International journal of dermatology.

[67]  E. Erken,et al.  Smoking and Behçet’s Disease , 2000, Clinical Rheumatology.

[68]  S. Ohno,et al.  Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test. , 1988, The Journal of rheumatology.

[69]  S. Ohno,et al.  HLA-Bw51 and Behçet's disease. , 1978, JAMA.

[70]  S. Ohno,et al.  HL-A5 AND BEHCET'S DISEASE , 1973 .

[71]  H. Behcet.  UBER REZIDIVERENDE APHTHOSE DURCH EIN VIRUS VERURSACHTE GESCHWURE AM MUND, AM AUGE UND AN DEN GENITALIEN , 1937 .